Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Drug Development Beyond Borders - Today's Global Cooperative Clinical Trials -
August 7, 2006
- Wholesalers Have Not Yet Offered Rock-Bottom Prices: NPhA
August 7, 2006
- 28 Hospitals Participating in Shizuoka Clin. Trial Network
August 7, 2006
- Price Agreement Rate Exceeded 50% in 1st Qtr: Suzuken
August 7, 2006
- R&D NEWS IN BRIEF
August 7, 2006
- Nippon Chemiphar Aims for \10 Bil. in GE Drug Sales in FY2006
August 7, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 7, 2006
- Rate of Generic Drug Substitution Still Low: ASTEM
August 7, 2006
- e-Trial Proposes Multinational Trials Including China
August 7, 2006
- GENERIC NEWS IN BRIEF
August 7, 2006
- MEDICAL DEVICE NEWS IN BRIEF
August 7, 2006
- Approval of 32 Products Released
August 7, 2006
- All-case Studies Increasingly a Condition for Approval: OPIR
August 7, 2006
- Council Recommends Early Approval of 4 Drugs
August 7, 2006
- Chuikyo Listens to FPMAJ, PhRMA, EFPIA on Drug Pricing
August 7, 2006
- JMA Opposed to More Frequent NHI Price Revision
August 7, 2006
- SELF-MEDICATION NEWS IN BRIEF
August 7, 2006
- REGULATORY NEWS IN BRIEF
August 7, 2006
- Novo Nordisk Pharma to Cover GP Market in Future
July 31, 2006
- 3rd Science and Technology Forum
July 31, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…